ライフサイエンスコーパス: surfactant protein C

1 nd that up to 97% of cells were positive for surfactant protein C, 95% for mucin-1, 93% for surfactan

2 1 and downstream lung target genes including surfactant protein C and Clara cell secretory protein.

3 urfactant protein B deficiency, mutations in surfactant protein C and the ABCA3 transporter.

4 EGF treatment stimulated the expression of surfactant protein C and thyroid transcription factor-1

5 Gene expression of both surfactant protein-C and aquaporin-5 were inhibited in c

6 helial markers (Clara cell-specific protein, surfactant protein C, and aquaporin-5), and lack of surf

7 dicated by an increase in the AEC II marker, surfactant protein C, and decreases in the AEC I markers

8 I/II trial in North America of a recombinant surfactant protein C-based surfactant (Venticute) as tre

9 to four intratracheal doses of a recombinant surfactant protein C-based surfactant given within a per

10 We then used a Surfactant protein C-CreER(T2) knock-in allele to follow

11 istal epithelium of transgenic lungs using a surfactant protein C enhancer/promoter.

12 Inhibition of SCD reduced surfactant protein C expression and suppressed rhinoviru

13 However, attenuated endogenous surfactant protein C expression indicated that alveolar

14 Recent reports have linked mutations in the surfactant protein C gene (SFTPC) to familial forms of p

15 evented TGF-beta-mediated down-regulation of surfactant protein C gene expression, a marker of bronch

16 sion of Cre-recombinase under control of the surfactant protein C gene promoter.

17 pulmonary type II cells under control of the surfactant protein C gene promoter.

18 h a peptide model for collagen and pulmonary surfactant protein C have been simulated very closely by

19 ) conditional expression of a mutant form of surfactant protein C (L188Q SFTPC) found in familial int

20 Lungs of both naive surfactant protein C-MCP mice and influenza-infected WT

21 etic lineage-tracing experiments showed that surfactant protein C-positive (SFTPC-positive) AEC2s sel

22 Either deletion of TLR4 or HA synthase 2 in surfactant-protein-C-positive AEC2s leads to impaired re

23 liferative disease, including lung fibrosis (surfactant protein C precursor; pro-SP-C) and familial d

24 der conditional control of the lung-specific surfactant protein C promoter (SP-C-rtTA), to inhibit FG

25 that express a lung-specific TSLP transgene (surfactant protein C promoter (SPC)-TSLP) develop a spon

26 xpressing PPARgamma under the control of the surfactant protein C promoter had reduced expression of

27 human DPP4 (hDPP4) under the control of the surfactant protein C promoter or cytokeratin 18 promoter

28 mutant form of human p53 expressed from the surfactant protein C promoter sensitizes mice to bleomyc

29 Transgenic mice using the human Surfactant Protein C promoter to drive the expression of

30 Transgenic mice were established using surfactant protein C promoter to express human RON in th

31 solely in the lungs of GM-/- mice (using the surfactant protein C promoter) dramatically decreased th

32 hrough use of the Cre/loxP system, the human surfactant protein C promoter, and the reverse tetracycl

33 leting the integrin from E10.5 onwards using surfactant protein C promoter-driven Cre.

34 ssed as a transgene under the control of the surfactant protein C promoter.

35 that expressed OVA under the control of the surfactant protein C promoter.

36 genes under control of doxycycline-dependent surfactant protein C promoter.

37 promoter and, to a lesser extent, the human surfactant protein C promoter.

38 ular domain of Notch3 is expressed using the surfactant protein C promoter/enhancer.

39 r (EGFR) under the control of the human lung surfactant protein-C promoter exhibit decreased pulmonar

40 The BRICHOS domain from lung surfactant protein C proprotein (proSP-C) is required fo

41 and treated with 100 mg/kg recombinant human surfactant protein C (rSP-C) containing surfactant and v

42 We evaluated the efficacy of a recombinant surfactant protein-C (rSP-C) surfactant in vitro and in

43 We used the mouse surfactant protein C (Sftpc) promoter to over-express th

44 cEGFP in the epithelium under the control of surfactant protein C (Sftpc) regulatory elements expands

45 Expression of mutant surfactant protein C (SFTPC) results in endoplasmic reti

46 wild-type (SFTPC+/+) controls, mice lacking surfactant protein C (SFTPC-/-) had greater lung neutrop

47 Mutations in the genes encoding surfactant protein C, SFTPC, and a member of the adenosi

48 Mutations in the gene encoding SP-C (surfactant protein C; SFTPC) have been linked to interst

49 Biosynthesis of surfactant protein C (SP-C) by alveolar type 2 cells req

50 Mutations in the surfactant protein C (SP-C) gene (SFTPC) are associated

51 The surfactant protein C (SP-C) gene encodes an extremely hy

52 ed bearing a chimeric gene composed of human surfactant protein C (SP-C) gene promoter and the porcin

53 Surfactant protein C (SP-C) has been suggested to be an

54 ance of thioester-linked acyl groups in lung surfactant protein C (SP-C) in facilitating interactions

55 To determine the role of surfactant protein C (SP-C) in host defense, SP-C-defici

56 d protein overlapped with those of TTF-1 and surfactant protein C (SP-C) in the respiratory epithelia

57 Surfactant protein C (SP-C) is a hydrophobic 35-amino ac

58 Surfactant protein C (SP-C) is a hydrophobic lipopeptide

59 Surfactant protein C (SP-C) is a hydrophobic protein syn

60 Bovine pulmonary surfactant protein C (SP-C) is a hydrophobic, alpha-heli

61 Surfactant protein C (SP-C) is a lung-specific protein t

62 Surfactant protein C (SP-C) is a novel amyloid protein f

63 Surfactant Protein C (SP-C) is a secreted transmembrane

64 Surfactant protein C (SP-C) is expressed in alveolar Typ

65 Rat surfactant protein C (SP-C) is synthesized as a 194-amin

66 Surfactant protein C (SP-C) is synthesized by alveolar t

67 the respiratory region in the endoderm, and surfactant protein C (Sp-C) mRNAs.

68 ce overexpressing hCFTR in the lung from the surfactant protein C (SP-C) promoter (SP-C-hCFTR+/-).

69 ice under the transcriptional control of the surfactant protein C (SP-C) promoter, resulting in expre

70 ithelial type II cell-specific promoter--the surfactant protein C (SP-C) promoter.

71 riptional control of the lung-specific human surfactant protein C (SP-C) promoter.

72 ungs of transgenic mice under control of the surfactant protein C (SP-C) promoter.

73 eptor (dnAlk6), were overexpressed using the surfactant protein C (Sp-C) promoter/enhancer.

74 Proteolytic processing of surfactant protein C (SP-C) proprotein in multivesicular

75 R) retention, and degradation of the encoded surfactant protein C (SP-C) proprotein.

76 t cause misfolding of the encoded proprotein surfactant protein C (SP-C) trigger endoplasmic reticulu

77 Mice lacking the lung-specific protein surfactant protein C (Sp-C) were lethally irradiated, tr

78 High levels of surfactant protein C (Sp-C), thyroid transcription facto

79 3 and targeted deletion of the gene encoding surfactant protein C (SP-C), was associated with either

80 Expression of surfactant protein C (SP-C), which is restricted to alve

81 Surfactant protein C (SP-C; Sftpc) gene expression is re

82 Transcription of the surfactant protein-C (SP-C) gene is restricted to Type I

83 r the control of the promoter from the human surfactant protein-C (SP-C) gene.

84 of regulatory elements from either the human surfactant protein-C (SP-C) or rat Clara cell secretory

85 ession using a construct of the 3.7-kb human surfactant protein-C (SP-C) promoter and the rat PGIS cD

86 ected against the ATII cell-specific antigen surfactant protein-C (SP-C) then administered to C57BL/6

87 throughout the distal epithelium, using the surfactant protein-C (SP-C)-enhancer/promoter.

88 t protein-B (SP-B1-78) (B) and palmitoylated surfactant protein-C (SP-C1-35) (C), and synthetic KL4 p

89 e expressing GM-CSF only in the lungs from a surfactant protein C (SPC) promoter (SPC-GM(+/+)/GM(-/-)

90 GF-A) in the distal lung epithelium from the surfactant protein C (SPC) promoter were generated to in

91 press the PDGF-B gene from the lung-specific surfactant protein C (SPC) promoter.

92 conditionally target K-RasG12D expression in Surfactant Protein C (SPC)(+) alveolar type 2 cells and

93 , NKX2.1 protein, and its downstream target, surfactant protein C (SpC).

94 ere treated with 100 mg/kg recombinant human surfactant protein-C surfactant and ventilated for 2 or

95 lack of expression of surfactant protein B, surfactant protein C, the Clara cell secretory protein,